Aki Kangasmäki

Learn More
BACKGROUND AND PURPOSE Few studies have concerned the absolute apparent diffusion coefficient (ADC) values in the normal human brain and the effect of aging on diffusion. Therefore, our purpose was to determine whether the average ADC (ADC(av)) values in the various regions of the brain differ with age, sex, or hemisphere and to establish reference values(More)
Four different postprocessing methods to determine cerebral blood volume (CBV) and contrast agent mean transit time (MTT) by dynamic susceptibility contrast (DSC) MRI were compared. CBV was determined by two different methods that integrate tracer concentration-time curves numerically and by two other methods that take recirculation into account. For the(More)
BACKGROUND AND PURPOSE The determination of cerebral blood flow heterogeneity (FH) by dynamic susceptibility contrast (DSC) magnetic resonance imaging has recently been proposed as a tool to predict final infarct size in acute stroke. In this study, we describe the evolution of FH during the first week as well as its correlation to the patients' clinical(More)
We explored functional brain changes with positron emission tomography (PET) in mild cognitive impairment (MCI) patients and elderly normal controls by employing an episodic memory task that included two successive encoding trials of semantically related word-pairs and final retrieval. Both groups demonstrated significant learning across the two trials. The(More)
To the best of our knowledge, imaging of accidental exposure to radioactive fluorine-18 (F-18) due to liquid spill has not been described earlier in the scientific literature. The short half-life of F-18 (t½=110 min), current radiation safety requirements, and Good Manufacturing Practice (GMP) regulations on radiopharmaceuticals have restrained the(More)
Radium-223-dichloride ((223)RaCl₂) is a new bone-seeking calcium analogue alpha-emitter, which has obtained marketing authorization for the treatment skeletal metastases of hormone-refractory prostate cancer. The current treatment regimen is based on six consecutive doses of (223)RaCl₂ at 4 week intervals and the administered activity dose, 50 kBq/kg per(More)
  • 1